BioNTech plans share sale with Pfizer logging large order

German biotech company BioNTech said on Tuesday it plans to raise cash in a share sale that will see its coronavirus vaccine partner Pfizer Inc become a shareholder. The rights offering announcement is the latest in a flurry of financing activity this week around German biotech companies that are racing to develop potential vaccines against the novel coronavirus. Shares in BioNTech, whose market capitalisation stands at $21 billion, surged 7% to $94.47 by 1400 GMT.